Niagen Bioscience, Inc. financial data

Symbol
NAGE on Nasdaq
Location
Los Angeles, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 382% % 45%
Quick Ratio 64% % -1.5%
Debt-to-equity 44% % -45%
Return On Equity 35% % 613%
Return On Assets 24% % 790%
Operating Margin 15% % 3074%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79,806,139 shares 4.5%
Common Stock, Shares, Outstanding 79,639,000 shares 4.8%
Entity Public Float $142,700,000 USD 76%
Common Stock, Value, Issued $79,000 USD 3.9%
Weighted Average Number of Shares Outstanding, Basic 79,779,000 shares 5%
Weighted Average Number of Shares Outstanding, Diluted 86,619,000 shares 11%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $124,709,000 USD 36%
Cost of Revenue $45,027,000 USD 27%
Research and Development Expense $5,935,000 USD 1.3%
Selling and Marketing Expense $33,808,000 USD 24%
General and Administrative Expense $20,635,000 USD -9.3%
Operating Income (Loss) $19,304,000 USD 4219%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $21,252,000 USD 156%
Income Tax Expense (Benefit) $823,000 USD
Net Income (Loss) Attributable to Parent $20,429,000 USD 1276%
Earnings Per Share, Basic 0 USD/shares 2700%
Earnings Per Share, Diluted 0 USD/shares 2400%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $64,100,000 USD 99%
Accounts Receivable, after Allowance for Credit Loss, Current $8,506,000 USD 20%
Inventory, Net $18,791,000 USD 78%
Assets, Current $93,616,000 USD 80%
Operating Lease, Right-of-Use Asset $2,361,000 USD 24%
Intangible Assets, Net (Excluding Goodwill) $246,000 USD -38%
Other Assets, Noncurrent $417,000 USD 11%
Assets $98,139,000 USD 74%
Accounts Payable, Current $12,742,000 USD 85%
Accrued Liabilities, Current $8,700,000 USD -9.3%
Liabilities, Current $22,712,000 USD 28%
Contract with Customer, Liability, Noncurrent $2,674,000 USD 3.7%
Operating Lease, Liability, Noncurrent $2,077,000 USD 11%
Liabilities $27,463,000 USD 24%
Retained Earnings (Accumulated Deficit) $168,660,000 USD 11%
Stockholders' Equity Attributable to Parent $70,676,000 USD 106%
Liabilities and Equity $98,139,000 USD 74%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,883,000 USD 2572%
Net Cash Provided by (Used in) Financing Activities $3,105,000 USD
Net Cash Provided by (Used in) Investing Activities $32,000 USD 22%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 79,639,000 shares 4.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,956,000 USD 4465%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $64,290,000 USD 98%
Deferred Tax Assets, Valuation Allowance $44,290,000 USD -4.5%
Deferred Tax Assets, Gross $44,676,000 USD -4.4%
Operating Lease, Liability $3,053,000 USD 6%
Depreciation $158,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid $3,438,000 USD 9.7%
Operating Lease, Liability, Current $976,000 USD -3.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two $782,000 USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,183,000 USD 4.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 15%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $385,000 USD 53%
Lessee, Operating Lease, Liability, to be Paid, Year Three $657,000 USD 34%
Deferred Tax Assets, Operating Loss Carryforwards $35,224,000 USD -4.1%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $338,000 USD -5.6%
Operating Lease, Payments $295,000 USD 224%
Additional Paid in Capital $239,266,000 USD 7.1%
Amortization of Intangible Assets $37,000 USD -2.6%
Deferred Tax Assets, Net of Valuation Allowance $386,000 USD 7.8%